4 min read
A Singapore Marketing Authorization Holder (MAH) plays a far more critical role than many pharmaceutical companies initially realize. Beyond serving as the local representative to Singapore's Health Sciences Authority (HSA), the MAH is responsible for maintaining product registrations, managing Regulatory obligations, overseeing post-market responsibilities, and ensuring ongoing compliance throughout the product lifecycle.
To better understand what this responsibility looks like in practice, we sat down with Freyr's Singapore Regulatory expert to discuss common misconceptions, key responsibilities, and lessons learned from supporting companies entering the Singapore market.
Meet the Expert
With over 20 years of experience across pharmaceuticals, biologics, and medical devices, our Singapore Regulatory lead has navigated markets spanning Canada, the US, EU, GCC, Africa, CIS, LATAM, India, and APAC.
He's led end-to-end registrations, authored CTD dossiers, managed post-approval variations, and sat across the table from health authorities in some of the most complex Regulatory environments in the world. When it comes to Singapore, he knows exactly where companies get it right — and where they don't.
So, let's start simply — what is a MAH, and why does it matter so much in Singapore?
I get this question a lot — often from companies that are further along in their Singapore plans than they should be without knowing the answer. A Marketing Authorization Holder is the locally registered Singapore company that officially holds your product registration with HSA Singapore. They submit applications, communicate with the authority, and carry full legal responsibility for the product.
The Marketing Authorization Holder (MAH) in Singapore is a company or legal entity who is authorized for sale a pharmaceutical product by the Health Sciences Authority (HSA). Appointing an MAH is mandatory for foreign manufacturers and requires a local registered company.
What surprises people is how absolute this requirement is. HSA doesn't deal with your head office in Germany or your manufacturing site in India. They deal with your Singapore entity. Full stop.
Who can take on the MAH role?
It must be a Singapore-registered company — there's no workaround. That said, the MAH can appoint authorized representatives to handle specific procedures on their behalf. So, it's not as rigid operationally as it sounds. But the legal anchor must always be local.
What does the MAH actually own once a product is approved?
Everything. I always tell clients — the MAH role doesn't end at approval; it begins there.
The MAH remains responsible for supporting Therapeutic Product Registration Singapore requirements throughout the product lifecycle, including variations, renewals, post-market safety monitoring, and Regulatory reporting obligations. And if anything, new emerges that affects the product's safety or benefit-risk profile, HSA needs to know immediately. Not eventually.
Does all communication with HSA have to go through the MAH?
Yes, all of it. Commitment letters, safety reports, defect notices, recall notifications — the MAH is the sole legal entity for every official exchange. I've seen companies try to manage HSA communications informally through a regional team that wasn't the registered MAH. It created confusion, slowed responses, and cost them time on something time sensitive. The structure exists for a reason.
Case Study: Registering a 16-Product Biologics Portfolio with HSA
Client: India-based pharmaceutical company I Product type: Biologics
What was the client trying to do?
Register 16 biologic products across 40 strengths with Singapore's HSA — a significant undertaking given the scientific complexity of biologics and the rigor of HSA's requirements.
What were the biggest challenges?
Proving quality, safety, and efficacy for biological drugs requires a level of documentation that goes well beyond standard pharmaceuticals. On top of that, Regulatory requirements for biologics can vary considerably across product types, making consistency across a large portfolio especially difficult to maintain.
Where did Freyr come in?
From the very beginning — feasibility assessment, Regulatory strategy, dossier gap analysis, equivalence study planning, and full submission to HSA. We then stayed actively involved through post-registration variations and HSA query responses.
What did the client walk away with?
A cleaner, faster registration process driven by a complete and well-prepared application. Full Regulatory Compliance Singapore requirements were met, while structured milestone tracking ensured transparency throughout the project— the client always knew exactly where things stood.
Partnering with a Singapore Marketing Authorization Holder (MAH) allowed the client to secure the necessary legal framework for HSA registration and full commercial freedom to manage distributors as established by HSA. This partnership provided a locally registered compliant entity for regulatory accountability, pharmacovigilance, and intellectual property protection, without the need for a physical office in Singapore.
Any final thought for companies planning to enter Singapore?
Don't treat the MAH as a box to tick. The companies that do well in Singapore are the ones that treat it as a relationship — with HSA, with their local entity, with their product's full lifecycle. Get the structure right before you launch, and you'll spend far less time firefighting later.
The risk involved in Distributor-Owned Licenses involve Locked-In Partnerships, hostage Licenses and conflicting Priorities. Hence, Companies should investigate and hire an independent, third-party MAH service provider to hold the licenses. This ensures commercial flexibility, IP Protection and Unbiased Compliance.
Conclusion
Singapore Marketing Authorization Holder (MAH) responsibilities extend far beyond product registration. Companies that view the MAH as a strategic Regulatory partner rather than simply a local representative are generally better positioned to manage compliance, respond effectively to HSA requirements, and support long-term success in the Singapore market. Getting the MAH structure right before launch can save significant time, effort, and Regulatory risk later in the product lifecycle.
To learn more about how Freyr can support your Regulatory needs in Singapore, fill out the contact form or write to us at sales@freyrsolutions.com.
